Skip to content

Clinical trials

Phase 1/2 Ovarian Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Ovarian Neoplasms Phase: Phase 1/2 Country / region: China Clear all

49 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20141
20151
20162
20171
20182
20191
20201
20216
20222
20235
20247
202512
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting24
Completed6
Active, not recruiting6
Unknown status5
Terminated4
Not yet recruiting2
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Beijing Biotech4
Anhui Provincial Cancer Hospital3
AstraZeneca3
Essen Biotech3
Shenzhen Geno-Immune Medical Institute3
Fuda Cancer Hospital, Guangzhou2
Genmab2
Jacobio Pharmaceuticals Co., Ltd.2
Shenzhen Ionova Life Sciences Co., Ltd.2
Acerand Therapeutics (Shanghai) Limited1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Ovarian Neoplasms49
Breast Neoplasms14
Colorectal Neoplasms10
Endometrial Neoplasms10
Pancreatic Neoplasms10
Stomach Neoplasms9
Lung Neoplasms7
Uterine Cervical Neoplasms7
Carcinoma, Non-Small-Cell Lung6
Neoplasms6

Trials

Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.